Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: what is the evidence?
作者机构:Research CenterMontreal Heart InstituteMontrealQCCanada Faculty of PharmacyUniversitéde MontréalMontrealQCCanada UniversitéParis CitéINSERMInnovative Therapies in HaemostasisParisFrance Service d’Hématologie BiologiqueAP-HPHôpital LariboisièreParisFrance
出 版 物:《Neural Regeneration Research》 (中国神经再生研究(英文版))
年 卷 期:2024年第19卷第3期
页 面:536-541页
核心收录:
学科分类:0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100204[医学-神经病学] 10[医学]
基 金:Fujimori Kogyo
主 题:Alzheimer’s disease amyotrophic lateral sclerosis biomarker dementia diabetic neuropathy nerve growth factor receptor(NGFR) neurodegeneration p75^(NTR) schizophrenia
摘 要:Neurodegenerative diseases are often misdiagnosed,especially when the diagnosis is based solely on clinical *** p75 neurotrophic receptor(p75^(NTR))has been studied as an index of sensory and motor nerve development and *** cleavable extracellular domain(ECD)is readily detectable in various biological fluids including plasma,serum and *** is evidence for increased p75NTR ECD levels in neurodegenerative diseases such as Alzheimer’s disease,amyotrophic lateral sclerosis,age-related dementia,schizophrenia,and diabetic *** p75^(NTR) ECD could be used as a biomarker for diagnosis and/or prognosis in these disorders,and whether it could potentially lead to the development of targeted therapies,remains an open *** this review,we present and discuss published studies that have evaluated the relevance of this emerging biomarker in the context of various neurodegenerative *** also highlight areas that require further investigation to better understand the role of p75^(NTR) ECD in the clinical diagnosis and management of neurodegenerative disorders.